Peptide/Protein Ingredients TRIZ Cases

Cardiotrophin-1 administration reverses maladaptive remodeling in pulmonary hypertension, sustaining contractile function.

Exosome-mediated delivery of sphingosine kinase 2 and ceramide induces hepatocyte proliferation, addressing inadequate repair after ischemia reperfusion injury.

Colocasia root extract reduces lung tumor colonies and modulates immune responses, addressing high toxicity in conventional metastatic cancer therapies.

Subcutaneous botulinum toxin injection reduces Substance P and CGRP levels, alleviating liver fibrosis without systemic side effects.

Conjugating peptides to high-density brush polymers protects them from protease degradation, enabling systemic administration and extended circulation times.

A TRAIL trimer construct targets mesothelin-positive cells to induce apoptosis via death receptor engagement.

Elastin-like polypeptide carriers modulate molecular size to achieve specific renal cortex and medulla accumulation.

Combining a CXCR2 agonist with a CXCR4 antagonist reduces graft-versus-host disease risk by altering the mobilized cell composition.

Modified peptides bind the bacterial beta clamp hydrophobic pocket, resolving insufficient natural ligand affinity.

Adropin stimulating agents trigger internal production to shrink tumors, bypassing complex direct dosing protocols.

Modified GIP analogs and hybrids resist DPP-IV degradation to extend half-life, addressing the short duration of action in native incretin therapies.

Amino acid substitutions in Factor IX increase specific activity, reducing dosage frequency and improving treatment efficacy for hemophilia B.

GHRH agonists bypass the GH/IGF-I axis to reduce infarct size and fibrosis without adverse effects.

CHO cell expression yields recombinant SAP with alpha2,3-linked sialic acids to improve stability and potency over wild-type forms.

Lipid pre-formulations form liquid crystals to sustain pasireotide release and reduce irritation.

A PEGylated chimeric canine urate oxidase protein maintains high enzyme activity through specific succinimidyl propionate linkage.

Oligomeric ACE2 constructs resolve low affinity bottlenecks by enhancing binding avidity to the viral S protein via multivalent interactions.

Nanosized prasugrel enhances bioavailability to reduce HCV-RNA while minimizing toxicity from interferon and ribavirin.

Chromatographic separation removes prothrombin contamination to reduce thrombotic risks and enable stable storage at higher temperatures.

Alkaline phosphatase preserves renal function by mitigating kidney damage caused by dialysis stress and nephrotoxic agents.

Therapeutic mRNA complexes with 3E10 antibodies enable efficient parenteral delivery to specific tissues.

Combining pegylated interleukin-10 with checkpoint inhibitors maintains stable serum trough concentrations.

IL-22 therapy restores thymic epithelial cell function and boosts T-cell production damaged by chemotherapy or radiation.

PARP inhibitors induce controlled DNA damage in megakaryocytes, accelerating platelet count recovery beyond TPO mimetics.

A protein formulation uses Tris buffer to maintain pH stability.

Peptoids inhibit RAGE expression and cytokine production, addressing inadequate treatment outcomes in Alzheimer's disease.

Metal sulfides adsorb and convert mercury species into stable compounds, bypassing interference from NOx and SO2 in flue gas.

Depleting glycogen stores via a ketogenic diet sensitizes cancer cells to tyrosine derivatives, reducing tumor size without increasing treatment complexity.

Topical hsp90α peptides stimulate cell migration to overcome chronic wound inefficiencies, replacing costly growth factor therapies with endogenous signaling.

Cyclic peptides with disulfide bonds inhibit alpha-synuclein fibrillation, reducing neurotoxicity in amyloid disorders.

A humanized anti-MSLN antibody binds to mesothelin-expressing cancer cells with high affinity and specificity.

A tissue scaffold incorporating platelet-derived growth factor recruits endogenous progenitor cells to damaged sites.

A chimeric uricase combines fungal catalytic domains with human C-terminal regions to lower immune response risks.

Surfactant protein D reduces parasite burden by enhancing host immune responses against parasitic nematodes.

PEGylation of cysteine variants extends circulating half-lives, reducing injection frequency and treatment costs.

Segmented arrestin-3 peptides selectively inhibit or activate JNK3 signaling, resolving the contradiction between targeted efficacy and systemic toxicity.

A high-selectivity polypeptide inhibitor blocks factor XIIa activation without affecting other coagulation factors.

Pre-therapy bioinformatic screening and post-administration monitoring of potential off-target sites determine gene editing suitability.

Engineered multimeric polypeptides achieve selective T-cell activation via localized binding affinity, minimizing non-specific immune responses.

Synthetic linear polypeptides replace heterogeneous natural protamine to eliminate allergic risks and ensure precise dosing.

An immunogenic composition combines tumor antigens with interferon-beta receptor agonists to stimulate robust immune responses.

SpHtp1 fusion protein enables fish cell translocation, reducing injection stress and adjuvant use.

Liquid Factor VIII formulation maintains potency for 100 days by removing degrading proteases via affinity chromatography, resolving stability constraints.

Merges PD-L1 inhibitors with HPV vaccines to overcome immune suppression and enhance antitumor response.

Aprotic polar solvent prevents fibrillation, enabling stable low-dose glucagon for chronic hypoglycemia and weight control.

Clusterin glycoprotein binds histones to neutralize cytotoxic actions, addressing delayed plasma exchange efficacy in thrombotic microangiopathies.

Bile acid sequestrants bind gastric acids to protect the esophageal lining, addressing inter-patient variability in reflux treatment.

Merges CCR9 inhibition and anti-TNF alpha blocking to resolve multi-pathway lymphocyte infiltration limitations in inflammatory bowel disease therapy.

Jun inhibitor T-5224 reduces cardiomyocyte Jun expression to alleviate heart failure with preserved ejection fraction.